Page last updated: 2024-10-24

carmustine and Leukopenia

carmustine has been researched along with Leukopenia in 26 studies

Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.

Leukopenia: A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).

Research Excerpts

ExcerptRelevanceReference
"Sixty-five patients with multiple myeloma resistant to melphalan were randomized to receive cyclophosphamide, doxorubicin (Adriamycin), and prednisone (CAP) (30 patients) or carmustine (BCNU), doxorubicin, and prednisone (BAP) (35 patients)."9.05Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. ( Brunner, K; Henderson, ES; Henry, PH; Holland, JF; Kyle, RA; McIntyre, OR; Nawabi, IU; Pajak, TF, 1982)
"A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0."9.05Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. ( Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT, 1982)
"From January 1975 to May 1981, 25 consecutive patients with multiple myeloma (MM) were entered in a prospective study and treated with the M-2 protocol (melphalan, prednisone, cyclophosphamide, vincristine, and carmustine [BCNU])."7.66Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). ( Carbone, A; Crivellari, D; Galligioni, E; Grigoletto, E; Tirelli, U; Trovò, MG; Tumolo, S; Veronesi, A, 1982)
"Sixty-five patients with multiple myeloma resistant to melphalan were randomized to receive cyclophosphamide, doxorubicin (Adriamycin), and prednisone (CAP) (30 patients) or carmustine (BCNU), doxorubicin, and prednisone (BAP) (35 patients)."5.05Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. ( Brunner, K; Henderson, ES; Henry, PH; Holland, JF; Kyle, RA; McIntyre, OR; Nawabi, IU; Pajak, TF, 1982)
"A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0."5.05Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. ( Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT, 1982)
"Two hundred fifty-two previously untreated evaluable patients with multiple myeloma were entered into a study testing a regimen of three intravenous alkylating agents, melphalan, cyclophosphamide, and carmustine (BCNU), given in combination (BCMP) against a regimen employing oral melphalan (MP)."5.04Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB. ( Coleman, M; Cooper, MR; Cuttner, J; Harley, JB; Kochwa, S; McIntyre, OR; Pajak, TF, 1979)
"Twenty-three patients with metastatic melanoma were treated with combination therapy consisting of dacarbazine (220 mg/m2) and cisplatin (25 mg/m2) iv daily for 3 days every 3 weeks, carmustine (150 mg/m2) iv every 6 weeks, and tamoxifen (10 mg) orally twice daily."3.67Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. ( Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF, 1987)
"From January 1975 to May 1981, 25 consecutive patients with multiple myeloma (MM) were entered in a prospective study and treated with the M-2 protocol (melphalan, prednisone, cyclophosphamide, vincristine, and carmustine [BCNU])."3.66Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). ( Carbone, A; Crivellari, D; Galligioni, E; Grigoletto, E; Tirelli, U; Trovò, MG; Tumolo, S; Veronesi, A, 1982)
" The dosage of CCNU was 100 mg/m2 p."2.65The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study. ( Brunner, K; Cuttner, J; Falkson, G; Hansen, HH; Holland, JF; Nissen, NI; Pajak, TF; Selawry, OS; Spurr, CL, 1981)
"It is an effective drug in the treatment of malignant melanoma with better response rates in women than in men."2.64Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group. ( Hill, G; Johnson, RO; Krementz, E; Metter, G; Wilson, W, 1976)

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-199022 (84.62)18.7374
1990's3 (11.54)18.2507
2000's1 (3.85)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Crider, AM1
Lamey, R1
Floss, HG1
Cassady, JM1
Bradner, WJ1
Hua, XM1
Ren, XW1
Liu, FL1
Liu, Y1
Zhang, CJ1
Li, ZJ1
Xu, L1
Liu, JY1
Liu, YG1
Stewart, DJ1
Benoit, B1
Richard, MT1
Hugenholtz, H1
Dennery, J1
Russell, N1
Peterson, E1
Grahovac, Z1
Belanger, G1
Maroun, JA1
Bonnet, JD1
Alexanian, R1
Salmon, SE1
Haut, A1
Dixon, DO1
Robustelli della Cuna, G1
Paoletti, P1
Bernardo, G1
Knerich, R1
Butti, G1
Cuzzoni, Q1
Oken, MM1
Costello, WG1
Johnson, GJ1
Lenhard, RE1
Ezdinli, EZ2
Orlow, E1
Barnes, JM1
Berard, CW1
Glick, JH2
Tirelli, U1
Crivellari, D1
Carbone, A1
Veronesi, A1
Galligioni, E1
Trovò, MG1
Tumolo, S1
Grigoletto, E1
Hansen, HH1
Selawry, OS1
Pajak, TF4
Spurr, CL1
Falkson, G1
Brunner, K3
Cuttner, J3
Nissen, NI1
Holland, JF2
Kyle, RA2
Henderson, ES1
Nawabi, IU1
Henry, PH1
McIntyre, OR3
Cornwell, GG1
Kochwa, S2
Glowienka, LP1
Rafla, S1
Silver, RT1
Cooper, MR2
Henderson, E1
Haurani, FI1
Brandes, AA1
Scelzi, E1
Zampieri, P1
Rigon, A1
Rotilio, A1
Amista, P1
Berti, F1
Fiorentino, MV1
Kleinberg, L1
Grossman, SA1
Piantadosi, S1
Zeltzman, M1
Wharam, M1
Harley, JB1
Coleman, M1
Johnson, RO1
Metter, G1
Wilson, W1
Hill, G1
Krementz, E1
Costanzi, JJ1
Case, DC1
Ervin, TJ1
Boyd, MA1
Redfield, DL1
Mbidde, EK1
Selby, PJ1
Perren, TJ1
Dearnaley, DP1
Whitton, A1
Ashley, S1
Workman, P1
Bloom, HJ1
McElwain, TJ1
McClay, EF1
Mastrangelo, MJ1
Bellet, RE1
Berd, D1
Anderson, JR1
Melvin, F1
Davis, TE1
O'Connell, MJ1
Tribalto, M1
Amadori, S1
Cantonetti, M1
Franchi, A1
Papa, G1
Pileri, A1
Boccadoro, M1
Dammacco, F1
Vacca, A1
Centurioni, R1
Desser, RK1
Ultmann, JE1
Fewer, D1
Wilson, CB1
Boldrey, EB1
Enot, KJ1
Powell, MR1
Tormey, DC1
Gailani, S1
Leone, L1
Cohen, SM1
Greenspan, EM1
Weiner, MJ1
Kabakow, B1
Gottlieb, JA1
Rivkin, SE1
Spigel, SC1
Hoogstraten, B1
O'Bryan, RM1
Delaney, FC1
Singhakowinta, A1
Kovach, JS1
Moertel, CG1
Schutt, AJ1
Hahn, RG1
Reitemeier, RJ1

Reviews

1 review available for carmustine and Leukopenia

ArticleYear
The sensitivity of Hodgkin's disease to chemotherapeutic agents administered singly.
    Series haematologica (1968), 1973, Volume: 6, Issue:2

    Topics: Adrenal Cortex Hormones; Alopecia; Antineoplastic Agents; Bleomycin; Blood Platelet Disorders; Carmu

1973

Trials

13 trials available for carmustine and Leukopenia

ArticleYear
[Comparision of high dose impulsion and low dose density chemotherapeutic regimens with paclitaxel plus cisplatin in advanced NSCLC].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2004, Volume: 26, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-C

2004
The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study.
    Cancer, 1981, Jan-01, Volume: 47, Issue:1

    Topics: Adult; Carmustine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration S

1981
Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.
    Cancer treatment reports, 1982, Volume: 66, Issue:3

    Topics: Aged; Antineoplastic Agents; Carmustine; Cyclophosphamide; Doxorubicin; Drug Resistance; Drug Therap

1982
Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience.
    Cancer, 1982, Nov-01, Volume: 50, Issue:9

    Topics: Antineoplastic Agents; Carmustine; Drug Administration Schedule; Drug Therapy, Combination; Female;

1982
Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas.
    American journal of clinical oncology, 1997, Volume: 20, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo

1997
Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB.
    Blood, 1979, Volume: 54, Issue:1

    Topics: Alkylating Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Humans; Leukopenia; Melp

1979
Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
    Cancer treatment reports, 1976, Volume: 60, Issue:2

    Topics: Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Femal

1976
DTIC (NSC-45388) studies in the southwest oncology group.
    Cancer treatment reports, 1976, Volume: 60, Issue:2

    Topics: Carmustine; Chlorpromazine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Co

1976
Waldenström's macroglobulinemia: long-term results with the M-2 protocol.
    Cancer investigation, 1991, Volume: 9, Issue:1

    Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dru

1991
Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985, Volume: 3, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Follow-Up Stud

1985
Treatment of multiple myeloma: a randomized study of three different regimens.
    Leukemia research, 1985, Volume: 9, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Carmustine; Clinical Trials as

1985
The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine.
    JAMA, 1972, Oct-30, Volume: 222, Issue:5

    Topics: Astrocytoma; Brain Neoplasms; Carcinosarcoma; Carmustine; Cerebral Angiography; Ependymoma; Evaluati

1972
Triple combination chemotherapy of disseminated melanoma.
    Cancer, 1972, Volume: 29, Issue:6

    Topics: Aged; Alkylating Agents; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Drug Combinati

1972

Other Studies

12 other studies available for carmustine and Leukopenia

ArticleYear
Synthesis of nitrosourea derivatives of pyridine and piperidine as potential anticancer agents.
    Journal of medicinal chemistry, 1980, Volume: 23, Issue:8

    Topics: Animals; Antineoplastic Agents; Leukemia, Experimental; Leukopenia; Mice; Neoplasms, Experimental; N

1980
Treatment of malignant gliomas in adults with BCNU plus metronidazole.
    Journal of neuro-oncology, 1984, Volume: 2, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Female; Gliobl

1984
Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
    Cancer treatment reports, 1984, Volume: 68, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Doxorubicin; Drug

1984
Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.
    Neurosurgery, 1982, Volume: 11, Issue:3

    Topics: Bone Marrow Diseases; Brain Neoplasms; Carmustine; Gastrointestinal Diseases; Glioblastoma; Glioma;

1982
The influence of histologic subtype on toxicity and response to chemotherapy in non-hodgkin's lymphoma. An Eastern Cooperative Oncology Group Study utilizing the BCVP regimen.
    Cancer, 1983, May-01, Volume: 51, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide;

1983
Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
    Cancer treatment reports, 1982, Volume: 66, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cycl

1982
The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma.
    International journal of radiation oncology, biology, physics, 1999, Jun-01, Volume: 44, Issue:3

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Ci

1999
High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.
    British journal of cancer, 1988, Volume: 58, Issue:6

    Topics: Adult; Bone Marrow; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Ther

1988
Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.
    Cancer treatment reports, 1987, Volume: 71, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Fem

1987
Phase II evaluation of BCNU and 5-FU in gastrointestinal carcinomas.
    Oncology, 1974, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Carmustine; Colonic Neoplasms; Diarrhea; Fluorouracil; Hematoc

1974
Proceedings: Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma. A Southwest Cancer Chemotherapy study Group study.
    Cancer, 1974, Volume: 33, Issue:2

    Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Carmustine; Cyclohexanes; Doxorubicin; Female; Humans

1974
Proceedings: A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer.
    Cancer, 1974, Volume: 33, Issue:2

    Topics: Adenocarcinoma; Carmustine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leukopenia; Mal

1974